|
|
|
| Progress on broadly neutralizing antibodies against human immunodeficiency virus type 1 |
| ZHANG Ziling, LIU Mingbin, XU Jianqing, ZHANG Xiaoyan |
| Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China |
|
|
|
|
Abstract The morbidity and mortality caused by human immunodeficiency virus type 1 (HIV)/acquired immunodeficiency syndrome (AIDS) were significantly controlled through the combination of anti-HIV-1 therapy. However, HIV/AIDS still could not be cured because of the persistence of HIV-1 reservoir. The broadly neutralizing antibody (bNAb) can effectively reduce the HIV-1 viral load and slow down disease progress, which might be an effective strategy to control HIV/AIDS. The practice of sequential immune strategies has greatly promoted the development of bNAbs. In March 2018, US Food and Drug Administration (FDA) approved the first monoclonal bNAb for the treatment of adult with multidrug resistant HIV, which greatly inspired the enthusiasm for bNAb development. The present paper reviewed the research progress and challenging on bNAb development in recent years.
|
|
Received: 26 November 2018
Published: 25 August 2019
|
|
Corresponding Authors:
ZHANG Xiaoyan
|
|
|
|
|
|
|
2019, Vol. 14 
